Angioedema News and Research

RSS

Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis.

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

25 Oct 2024

Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

Emerging personalized treatment approaches for chronic urticari.

16 Jul 2024

Berotralstat: A promising oral treatment for hereditary angioedema with normal C1-inhibitor

BioCryst Pharmaceuticals, Inc. today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily berotralstat.

8 Jun 2024

Hemp seed protein shows promise in lowering blood pressure

A study in The American Journal of Clinical Nutrition shows that hemp seed protein and its bioactive peptide can significantly lower blood pressure in mildly hypertensive adults, offering a potential dietary intervention for managing hypertension.

7 May 2024

Breakthrough gene-editing therapy transforms lives of patients with a hereditary disorder

A group of patients with a hereditary disorder have had their lives transformed by a single treatment of a breakthrough gene-editing therapy, according to the lead researcher.

2 Feb 2024

Rising incidence of kiwifruit allergy in children: study highlights severe allergic reactions

Study aimed to compile Kiwifruit allergy recognition patterns to enhance patient management and clinical practice.

6 Jul 2023

From delicacy to danger: The rising tide of shellfish allergies in children revealed

Shellfish consumption is on the rise, but so are shellfish allergies, particularly among children. A recent review delves into the epidemiology, symptoms, diagnosis, and management of shellfish allergies, highlighting the need for improved diagnostic tools and potential allergen immunotherapy.

13 Jun 2023

Processed danger: Industrial food additives and the health risks to children

Researchers explore the potential negative health effects on children due to the use of industrial additives in processing.

23 May 2023

Treatment using CRISPR genome editing alleviates swelling attacks in hereditary angioedema patients

Hereditary angioedema (HAE) is a rare, genetic disorder characterized by severe, recurring, and unpredictable swelling attacks in various organs and tissues of the body, which can be painful, debilitating, and life-threatening.

10 Nov 2022

Study elucidates why it takes a long time to diagnose life-threatening rare diseases

Regular episodes of severe pains in the abdomen and mysterious swellings had become the new normal for Yuki - for 20 years.

19 Apr 2022

Research reveals key differences between childhood and adult chronic spontaneous urticaria

New research presented at EADV 30th Congress today unveils key insights on the characteristic differences in chronic spontaneous urticaria in children versus adults.

3 Oct 2021

More popular type of antihypertensive drugs causes slightly more side effects

Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, but the more popular type causes slightly more side effects, finds a multinational observational study led by researchers at Columbia University Vagelos College of Physicians and Surgeons.

26 Jul 2021

Two types of blood pressure drugs provide equal benefits, but side effects differ

People who are just beginning treatment for high blood pressure can benefit equally from two different classes of medicine - angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - yet ARBs may be less likely to cause medication side effects, according to an analysis of real-world data published today in Hypertension, an American Heart Association journal.

26 Jul 2021

Latest ATS/CSL Behring research grant recipient focuses on COVID-19 ARDS study

The ATS Research Program is pleased to announce that William Zhang, MD, of Weill Cornell Medical Center is the recipient of the 2020-2021 ATS/CSL Behring Research Award in Acute Respiratory Distress Syndrome.

13 Jul 2021

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

FDA grants accelerated approval for first-of-its-kind Alzheimer's treatment

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer's, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

7 Jun 2021

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

FDA approves new indication for drug to treat pediatric NDO patients

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

25 Mar 2021

Innate immune system overreacts in patients with severe COVID-19

In patients with severe COVID-19, the innate immune system overreacts. This overreaction may underlie the formation of blood clots (thrombi) and deterioration in oxygen saturation that affect the patients.

23 Feb 2021